The commitment includes cash and in-kind grants in support of efforts to slow the spread of the virus and strengthen vulnerable healthcare systems against future public health threats. Most of the grants will be awarded over the next four to six weeks to the company's longtime nonprofit partners based on a previous evaluation of priority needs and partners' resource capabilities and gaps.
Through its Global Medical Grants program, the company will award a total of $5 million to proposals focused on improving the identification, diagnosis, treatment, and overall management of patients with COVID-19, while quality improvement grants will be awarded to medical centers, hospitals, and clinics in support of their efforts to improve the management and outcome of patients with COVID-19.
The company also plans to reconfigure its U.S. Patient Assistance Program to accommodate current challenges. In the United States, funds will be allocated to government public health organizations as well as charitable community health clinics; outside the U.S., funds will be allocated to international nongovernmental organizations (INGOs) and partners.
"We are in the midst of a global health crisis and understand the need for immediate and significant philanthropic and private sector contributions to help sustain local and global partners on the front lines of the pandemic response," said Caroline Roan, vice president, global health and patient access at Pfizer and president of the Pfizer Foundation. "At Pfizer, we believe it is our responsibility to help protect the most vulnerable from this disease and are putting the full weight of our resources behind our comprehensive COVID-19 response."